Urinary matrix metalloproteinase -8, -9, -14 and their regulators (TRY-1, TRY-2, TATI) in patients with diabetic nephropathy

Annals of Medicine

Volumn 40, Issue 4, 2008, Pages 312-320

  Lauhio, Anneli ^a   Sorsa, Timo ^b   Srinivas, Ravi ^b   Stenman, Mathias ^b   Tervahartiala, Taina ^b   Stenman, Ulf Håkan ^a   Grönhagen Riska, Carola ^a   Honkanen, Eero ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Diabetes mellitus; Diabetic nephropathy; Matrix metalloproteinase; MMP; MMP 14; MMP 8; MMP 9; TATI; Trypsin; Urinary

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; APROTININ; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATIN; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MATRIX METALLOPROTEINASE 14; NEUTROPHIL COLLAGENASE; TRYPSIN; TRYPSIN 1; TRYPSIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; FIBROBLAST; GELATINOLYTIC ACTIVITY; HUMAN; IMMUNOASSAY; IMMUNOFLUOROMMETRIC ASSAY; IMMUNOREACTIVITY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOLECULAR WEIGHT; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; URINALYSIS; WESTERN BLOTTING; ZYMOGRAPHY;

ADULT; AGED; BLOTTING, WESTERN; DIABETIC NEPHROPATHIES; FEMALE; FLUOROIMMUNOASSAY; HUMANS; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; TIME FACTORS; TRYPSIN; TRYPSIN INHIBITOR, KAZAL PANCREATIC; TRYPSINOGEN;

EID: 42449126565     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890801923746     Document Type: Article

References (53)

1. Zaoui P, Cantin J, Alimardani-Bessette M, Monier F, Halimi S, Morel F, et al. Role of metalloproteinases and inhibitors in the occurrence and progression of diabetic renal lesions. Diabetes Metab. 2000;26(Suppl 4):25-9.
2. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161-74.
3. Owen CA, Hu Z, Lopez-Otin C, Shapiro SD. Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase. J Immunol. 2004;72:7791-803.
4. Gueders MM, Balbin M, Rocks N, Foidart JM, Gosset P, Louis R, et al. Matrix metalloproteinase-8 deficiency promotes granulocytic allergen-induced airway inflammation. J Immunol. 2005;175:2589-97.
5. Lauhio A, Sorsa T, Lindy O, Suomalainen K, Saari H, Golub LM, et al. The anticollagenolytic potential of lymecycline in the long-term treatment of reactive arthritis. Arthritis Rheum. 1992;35:195-8.
6. Sorsa T, Salo T, Koivunen E, Tyynelä J, Konttinen Y, Bergmann U, et al. Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem. 1997;272:21067-74.
7. Marti HP. The role of matrix metalloproteinases in the activation of mesangial cells. Transpl Immunol. 2002;9:97-110.
8. Holopainen JM, Moilanen JA, Sorsa T, Kivela-Rajamaki M, Tervahartiala T, Vesaluoma MH, et al. Activation of matrix metalloproteinas-8 by membrane type 1-MMP and their expression in human tears after photorefractive keratectomy. Invest Ophthalmol Vis Sci. 2003;44:2550-6.
9. Moilanen M, Sorsa T, Stenman M, Nyberg P, Lindy O, Vesterinen J, et al. Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry. 2003;42:5414-20.
10. Ebihara I, Nakamura T, Shimada N, Koide H. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis. 1998;32:544-50.
11. Tashiro K, Koyanagi I, Ohara I, Ito T, Saitoh A, Horikoshi S, et al. Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal. 2004;18:206-10.
12. Honkanen E, Teppo AM, Törnroth T, Groop PH, Grönhagen-Riska. Urinary transforming growth factor-1 in membranous glomerulonephritis. Nephrol Dial Transplant. 1997;12:2562-8.
13. Lindy O, Konttinen YT, Sorsa T, Ding Y, Santavirta S, Ceponis A, et al. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum. 1997;40:1391-9.
14. Maisi P, Prikk K, Sepper R, Pirilä E, Salo T, Hietanen J, et al. Soluble membrane-type 1 matrix metalloproteinase (MT1-MMP) and gelatinase A (MMP-2) in induced sputum and bronchoalveolar lavage fluid of human bronchial asthma and bronchiectasis. APMIS. 2002;110:771-82.
15. Prikk K, Maisi P, Pirilä E, Reintman MA, Salo T, Sorsa T, et al. Airway obstruction correlates with collagenase-2 (MMP-8) expression and activation in bronchial asthma. Lab Invest. 2002;82:1535-45.
16. Sorsa T, Ding Y, Salo T, Lauhio A, Teronen O, Ingman T, et al. Effects of tetracyclines on neutrophil, gingival, and salivary collagenases. A functional and western-blot assessment with special reference to their cellular sources in periodontal diseases. Ann N Y Acad Sci. 1994;732:112-31.
17. Hanemaaijer R, Sorsa T, Konttinen YT, Ding Y, Sutinen M, Visser H, et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J Biol Chem. 1997;272:31504-9.
18. Lee HM, Golub LM, Cao J, Teronen O, Laitinen M, Salo T, et al. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer. Curr Med Chem. 2001;8:257-60.
19. Lukkonen A, Sorsa T, Salo T, Tervahartiala T, Koivunen E, Golub L, et al. Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration. Int J Cancer. 2000;86:577-81.
20. Paju A, Sorsa T, Tervahartiala T, Koivunen E, Haglund C, Leminen A, et al. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. Br J Cancer. 2001;84:1363-71.
21. Itkonen O, Koivunen E, Hurme M, Alfthan H, Schroder T, Stenman UH. Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis. J Lab Clin Med. 1990;115:712-8.
22. Osman S, Turpeinen U, Itkonen O, Stenman UH. Activation of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidinbiotin system. J Immunol Methods. 1993;161:97-106.
23. Hedstrom J, Leinonen J, Sainio V, Stenman UH. Time-resolved immunofluorometric assay of trypsin-2 complexed with alpha 1-antitrypsin in serum. Clin Chem. 1994;40:1761-5.
24. Gutierrez-Fernnandez A, Inada M, Balbin M, Fueyo A, Ana S, Pitiot AS, et al. Increased inflammation delays wound healing in mice deficient collagenase-2 (MMP-8). FASEB J. 2007;21:2580-91.
25. Kazes I, Delarue F, Hagege JN, Bouzhir-Sima L, Rondeau E, Sraer JD, et al. Soluble latent membrane-type 1 matrix metalloproteinase secreted by human mesangial cells is activated by urokinase. Kidney Int. 1998;54:1976-84.
26. Zhang Y, Wu XH, Cao GH, Li S. Relationship between expression of matrix metalloproteinase-9 (MMP-9) and angiogenesis in renal cell carcinoma. Ai Zheng. 2004;23:326-9.
27. Tervahartiala T, Pirilä E, Ceponis A, Bouzhir-Sima L, Rondeau E, Sraer JD, et al. The in vivo expression of the collagenolytic matrix metalloproteinases (MMP-2, -8, -13, and -14) and matrilysin (MMP-7) in adult and localized juvenile periodontitis. J Dent Res. 2000;79:1969-77.
28. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002;2:657-72.
29. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995;270:5331-8.
30. Knäuper V, Smith B, Lopez-Otin C, Murphy G. Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13). Eur J Biochem. 1997;248:369-73.
31. McLennan SV, Martell SY, Yue DK. High glucose concentration inhibits the expression of membrane type metalloproteinase by mesangial cells: possible role in mesangium accumulation. Diabetologia. 2000;43:642-8.
32. Kolb SA, Lahrtz F, Paul R, Leppert D, Nadal D, Pfister HW, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. J Neuroimmunol. 1998;84:143-50.
33. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225-32.
34. Overall CM. Regulation of tissue inhibitor of matrix metalloproteinase expression. Ann NY Acad Sci. 1994;732:51-64.
35. Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant. 2004;19:2987-96.
36. Locatelli F, Pozzoni P, Vecchio LD. Renal replacement therapy in patients with diabetes and end-stage renal failure. J Am Soc Nephrol. 2004;15:25-9.
37. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease. Diabetes. 2005;54:1626-34.
38. Lauhio A, Konttinen YT, Tscesche H, Nordström D, Salo T, Lähdevirta J, et al. Reduction of matrix metalloproteinases 8-neutrophil collagenase levels during long-term doxycycline treatment of reactive arthritis. Antimicrob Agents Chemother. 1994;38:400-2.
39. Lauhio A, Salo T, Ding Y, Konttinen YT, Nordström D, Tschesche H, et al. In vivo inhibition of human neutrophil collagenase (MMP-8) activity during long-term combination therapy of doxycycline and non-steroidal anti-inflammatory drugs (NSAID) in acute reactive arthritis. Clin Exp Immunol. 1994;98:21-8.
40. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12:12-26.
41. Suomalainen K, Sorsa T, Golub LM, Ramamurthy N, Lee HM, Uitto VJ, et al. Specificity of the anticollagenase action of tetracyclines: relevance to their anti-inflammatory potential. Antimicrob Agents Chemother. 1992;36:227-9.
42. Lauhio A, Salo T, Tjäderhane L, Lähdevirta J, Golub LM, Sorsa T. Tetracyclines in treatment of rheumatoid arthritis. Lancet. 1995;346:645-6.
43. Greenwald RA, Golub LM, Ramamurthy NS, Chowdhury M, Moak SA, Sorsa T. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation. Bone. 1998;22:33-8.
44. Sorsa T, Ramamurthy NS, Vernillo AT, Zhang X, Konttinen YT, Rifkin BR, et al. Functional sites of chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases. J Rheumatol. 1998;25:975-8.
45. Emingil G, Atilla G, Sorsa T, Savolainen P, Baylas H. Effectiveness of adjunctive low-dose doxycycline therapy on clinical parameters and gingival crevicular fluid laminin-5-gamma2 chain levels in chronic periodontitis. J Periodontol. 2004;75:1387-96.
46. Sorsa T, Tjäderhane L, Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis. 2004;10:311-8.
47. Meyer B, Meyer B, Salvatore M. Tetracyclines and chloramphenicol. In: Mandell D, Bennett G, Douglas R, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, 6th ed. Philadelphia: Elsevier, Churchill Livingstone, 2005. p. 356-72.
48. Naini EA, Harandi AA, Moghtaderi J, Bastani B, Amiran A. Doxycycline: a pilot study to reduce diabetic proteinuria. Am J Nephropathol. 2007;27:269-73.
49. Ahuja TS. Doxicycline decreases proteinuria in glomerulonephritis. Am J Kidney Dis. 2003;42:376-80.
50. Diamant M, Hanemaaijer R, Verheijen JH, Smith JW, Lemkes H. Elevated matrix metalloproteinase-2 and -9 in urine, but not in serum, are markers of type I diabetic nephropathy. Diabet Med. 2001;18:423-4.
51. Chang HR, Yang SF, Li ML, Lin CC, Hsieh YS, Lian JD. Relationships between circulating matrix metalloproteinases -2 and -9 and renal function in patients with chronic kidney diseases. Clin Chim Acta. 2006;366:243-8.
52. El Nahas MA, Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005;365:331-40.
53. Van Dijk PC, Jager KJ, Stengel B, Grönhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int. 2005;67:1489-99.